AMBBY:OTC-Ambu A/S (USD)

COMMON STOCK | Medical Devices | OTC

Last Closing Price

USD 8.08

Change

-0.30 (-3.58)%

Market Cap

USD 2.07B

Volume

357.00

Avg Analyst Target

N/A

Avg User Target

USD
Average Analyst Rating

N/A

Fundamental Analysis

Verdict


AMBBY Stock Forecast & Price:
Based on the Ambu A/S stock forecasts from 0 analysts, the average analyst target price for Ambu A/S is not available over the next 12 months. Ambu A/S’s average analyst rating is not available. Stock Target Advisor’s own stock analysis of Ambu A/S is Slightly Bearish, which is based on 5 positive signals and 8 negative signals. At the last closing, Ambu A/S’s stock price was USD 8.08. Ambu A/S’s stock price has changed by -7.34% over the past week, -17.47% over the past month and -75.68% over the last year.

No recent analyst target price found for Ambu A/S
No recent average analyst rating found for Ambu A/S

About Ambu A/S (AMBBY:OTC)

Ambu A/S develops, produces, and sells medical devices to hospitals, clinics, and rescue services worldwide. It provides healthcare solutions in the fields of visualization, anesthesia, and patient monitoring and diagnostics. The company offers endoscopy products, such as broncho ...Read More

Technical Indicators

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2022-09-27 )

Largest Industry Peers for Medical Devices

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
SMMNY Siemens Healthineers AG ADR

-0.25 (-1.23%)

USD46.91B 25.05 11.34
SEMHF Siemens Healthineers AG

N/A

USD46.14B 28.25 11.34
RYLPF Koninklijke Philips N.V

-0.30 (-1.92%)

USD14.73B 38.69 11.77
SONVY Sonova Holding AG

+0.08 (+0.19%)

USD13.40B 20.89 15.37
SONVF Sonova Holding AG

-3.22 (-1.47%)

USD13.40B 21.26 15.37
SNNUF Smith & Nephew plc

-0.14 (-1.31%)

USD9.90B 19.16 9.90
CHEOY CochLear Ltd ADR

-1.16 (-1.77%)

USD8.59B 44.06 18.26
CHEOF Cochlear Limited

N/A

USD8.59B 49.48 17.55
WILLF Demant A/S

N/A

USD6.01B 20.66 2.29
WILYY Demant A/S ADR

-0.26 (-2.00%)

USD5.87B 20.08 2.29

ETFs Containing AMBBY

Symbol Name Weight Mer Price(Change) Market Cap

N/A

Market Performance

  Market Performance vs.
Industry/Classification (Medical Devices)
Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -67.38% 23% F 15% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -67.38% 23% F 14% F
Trailing 12 Months  
Capital Gain -74.03% 24% F 18% F
Dividend Return 0.15% 7% F N/A N/A
Total Return -73.88% 25% F 17% F
Trailing 5 Years  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Average Annual (5 Year Horizon)  
Capital Gain 10.26% 48% F 53% F
Dividend Return 0.15% 11% F 6% F
Total Return 10.41% 48% F 49% F
Risk Return Profile  
Volatility (Standard Deviation) 62.83% 48% F 43% F
Risk Adjusted Return 16.56% 55% F 44% F
Market Capitalization 2.07B 87% B+ 77% C+
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 87%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Medical Devices)
Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio 69.83 17% F 8% F
Price/Book Ratio 3.76 51% F 26% F
Price / Cash Flow Ratio 6.32 20% F 20% F
EV/EBITDA 4.24 19% F 24% F
Management Effectiveness  
Return on Equity 5.42% 73% C 54% F
Return on Invested Capital 6.87% 58% F 62% D-
Return on Assets 1.33% 79% C+ 62% D-
Debt to Equity Ratio 13.92% 42% F 62% D-
Technical Ratios  
Dividend Yield 0.53% 23% F 3% F
Short Ratio N/A N/A N/A N/A N/A
Short Percent N/A N/A N/A N/A N/A
Beta 0.54 60% D- 65% D
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Ratings

Target Price Action Rating Action Analyst Rating Price Date

No discussions yet

User / Independent Analyst Ratings

User Name Target Rating Target Horizon (Months) Target Price User Analysis Date Comment

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

Superior return on assets

The company management has delivered better return on assets in the most recent 4 quarters than its peers, placing it in the top quartile.

Positive cash flow

The company had positive total cash flow in the most recent four quarters.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

Superior Revenue Growth

This stock has shown top quartile revenue growth in the previous 5 years compared to its sector.

What to not like:
High volatility

The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.

Below median total returns

The company has under performed its peers on annual average total returns in the past 5 years.

Below median dividend returns

The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.

Overpriced compared to earnings

The stock is trading high compared to its peers on a price to earning basis and is above the sector median.

Overpriced on cashflow basis

The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Highly leveraged

The company is in the bottom half compared to its sector peers on debt to equity and is highly leveraged. However, do check the news and look at its sector and management statements. Sometimes this is high because the company is trying to grow aggressively.

Overpriced on free cash flow basis

The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Low Earnings Growth

This stock has shown below median earnings growth in the previous 5 years compared to its sector